Wegovy vs Mounjaro: Which Weight Management Option Suits You?
What Is Wegovy: Understanding the Core Difference vs Mounjaro
What is Wegovy fundamentally comes down to its unique mechanism as a GLP-1 receptor agonist, distinctly different from Mounjaro's dual-target approach. Wegovy contains semaglutide, which specifically mimics the GLP-1 hormone that signals fullness to your brain, whilst Mounjaro's tirzepatide targets both GIP and GLP-1 receptors for a broader metabolic effect. Both are prescription-only medicines that require clinical assessment and must be used alongside a reduced-calorie diet and increased physical activity. The practical implications affect everything from your dosing schedule to storage requirements during travel.
When patients ask what is Wegovy compared to alternatives, the answer centres on proven clinical heritage and practical convenience. Wegovy follows a structured 5-dose escalation from 0.25mg to 2.4mg maintenance over 16 weeks, whilst Mounjaro uses 6 doses ranging from 2.5mg to 15mg with different timing intervals. Both medications are manufactured by leading pharmaceutical companies—Wegovy by Novo Nordisk and Mounjaro by Eli Lilly—and both are subject to MHRA additional monitoring with the Black Triangle (▼) symbol. Your prescriber can help determine which mechanism and dosing approach aligns better with your individual weight management goals and lifestyle factors.
Wegovy Pricing Breakdown: What Is Wegovy Going to Cost vs Mounjaro
Understanding what is Wegovy in terms of cost requires comparing each stage of your treatment journey with transparent UK pricing. Wegovy single pens start at £79.99 for 0.25mg (weeks 1-4 starter dose), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for 2.4mg maintenance doses. New customers apply discount code FIRST40 at checkout to reach these final prices, whilst returning customers use code DOSE25. EverydayMeds stocks both medications, allowing direct price comparison at equivalent treatment stages.
Bundle options provide treatment continuity without the complexity of multiple orders, though the primary benefit is convenience rather than cost savings. The Intro Duo (0.25mg & 0.5mg) costs £169.99, covering your first 8 weeks, whilst the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 provides doses for weeks 5-16. The Ultimate Stability Trio offers three 2.4mg maintenance pens for £649.99, ensuring consistent supply once you've reached your target dose. Mounjaro pricing follows a different structure due to its distinct dosing protocol, and both options include next-day cold-chain delivery once your prescription is approved by our clinical team.
Clinical Evidence: What Is Wegovy's Research Foundation vs Mounjaro Studies
What is Wegovy's clinical backing stems primarily from the comprehensive STEP trial programme, demonstrating significant weight management results when used alongside lifestyle modifications. In the landmark STEP 1 trial, patients taking Wegovy with diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). Additional STEP studies showed sustained results, with STEP 5 maintaining clinically studied weight loss at 2 years, whilst the recent SELECT trial demonstrated a 20% reduction in major cardiovascular events.
Mounjaro's clinical evidence comes from the SURMOUNT trial series, though direct comparison of percentage weight loss between trials isn't methodologically sound due to different study designs and participant populations. Both medications have undergone rigorous MHRA evaluation and received NICE recommendations for weight management in appropriate patients. The key distinction lies not in superior efficacy claims, but in how each medication's mechanism may suit different metabolic profiles and individual responses to treatment.
How Wegovy Works: What Is Wegovy's Mechanism of Action
What is Wegovy mechanistically involves mimicking your body's natural GLP-1 hormone, which is released from your intestines after eating to signal satiety to your brain. This prescription-only medicine binds to GLP-1 receptors in multiple locations, including appetite control centres in the hypothalamus, leading to reduced hunger and increased feelings of fullness after smaller meals. The weekly injection maintains steady medication levels, providing consistent appetite regulation throughout each dosing interval. Clinical studies suggest Wegovy may also reduce food cravings and the reward value of high-calorie foods by influencing brain pathways involved in food preference. Unlike rapid-acting appetite suppressants, Wegovy's effects build gradually through the dose escalation protocol, supporting sustainable eating pattern changes alongside your dietary modifications.
Ordering Process: What Is Wegovy's Path from Assessment to Delivery
Getting Wegovy begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, weight management goals, and any contraindications to GLP-1 receptor agonists. Our GPhC-registered prescribers (#9012878) review each assessment within 3 working days as standard, or 24 hours with express review, ensuring clinical appropriateness before issuing any prescription. Once approved, your Wegovy is dispatched via next-day delivery using specialised cold-chain packaging to maintain the required 2-8°C temperature throughout transit. The same streamlined process applies whether you're ordering single pens or multi-pen bundles, with automated prescription tracking and delivery notifications. Express prescribing incurs additional fees but ensures faster treatment initiation for patients who meet clinical criteria and have no complicating factors requiring extended review.
Storage and Practical Considerations: What Is Wegovy's Real-World Convenience
What is Wegovy's practical advantage becomes clear in storage flexibility, particularly for patients who travel frequently or have variable refrigeration access. Wegovy pens maintain potency for up to 6 weeks at room temperature below 30°C once removed from refrigeration, significantly longer than Mounjaro's 21-day room temperature limit. The FlexTouch pen design provides reliable dose delivery with clear dose windows and smooth injection mechanics, suitable for weekly self-administration in the thigh, upper arm, or abdomen. Dose escalation cannot be skipped or accelerated—you must progress through 0.25mg, 0.5mg, 1mg, and 1.7mg stages before reaching 2.4mg maintenance, typically requiring 16 weeks to reach full therapeutic dosing. Each pen contains 4 doses of the same strength, meaning your 0.25mg starter pen provides your first month of treatment, whilst maintenance 2.4mg pens last one month each. Proper injection technique and site rotation help minimise injection site reactions, and unused pens should be returned to refrigerated storage promptly to maximise their usable lifespan.
What Is Wegovy's Unique Position in Dual-Option Weight Management
Understanding what is Wegovy's strategic advantage requires recognising that EverydayMeds offers both Wegovy and Mounjaro, eliminating the need to switch pharmacies if your initial choice requires adjustment. This dual availability means your prescriber can recommend the most appropriate option based on your individual clinical profile, previous medication experiences, and lifestyle factors without supply limitations. Some patients may respond better to Wegovy's targeted GLP-1 approach, whilst others might benefit from Mounjaro's broader receptor targeting, and having both options ensures treatment flexibility.
The comparison isn't about declaring one medication superior, but about matching mechanism to individual needs through professional clinical guidance. Wegovy's established clinical heritage, convenient storage characteristics, and proven cardiovascular benefits in the SELECT trial provide one treatment pathway, whilst Mounjaro's innovative dual-target approach offers an alternative mechanism for patients who may not achieve optimal results with GLP-1-only therapy. Both require the same commitment to dietary changes and increased physical activity, and both carry similar monitoring requirements during treatment initiation and dose escalation phases.
Making Your Choice: What Is Wegovy's Role in Your Weight Management Strategy
What is Wegovy ultimately depends on how its specific characteristics align with your individual circumstances, medical history, and treatment preferences. Both Wegovy and Mounjaro are available from EverydayMeds with the same high standards of clinical review, cold-chain delivery, and ongoing support throughout your treatment journey. Your prescriber will consider factors including your BMI, any weight-related comorbidities, previous medication experiences, and practical considerations like travel requirements when recommending between these options. New customers can begin their clinical assessment today using discount code FIRST40, whilst returning customers apply code DOSE25 at checkout to access our competitive UK pricing. Remember that successful weight management with either medication requires commitment to lifestyle changes, regular monitoring, and patience during the dose escalation period before reaching full therapeutic effects. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your assessment and discover which prescription-only weight management option best supports your individual goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
